# MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)

> **NCT00506077** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 55 (actual)

## Conditions studied

- Paranoid Schizophrenia

## Interventions

- **DRUG:** MK0249
- **DRUG:** Comparator: Placebo (unspecified)

## Key facts

- **NCT ID:** NCT00506077
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2015-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00506077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00506077, "MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00506077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*